# HiberCell

Source: https://onco.cc/companies/hibercell/  
OnCo record `hibercell` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HiberCell is a New York biotech working on the biology of dormant, disseminated cancer cells; its yeast beta-glucan immunotherapy imprime PGG, inherited from Biothera, reached late-stage trials with checkpoint inhibitors.

## Summary

HiberCell, founded in 2019 in New York, develops therapies against cancer dormancy and relapse and acquired Biothera Pharmaceuticals, whose imprime PGG, a yeast-derived beta-glucan that primes innate immune cells, had been tested with pembrolizumab in breast cancer and melanoma. Its PERK inhibitor and other programmes are in early trials, and the Biothera-era phase 3 record sits on ClinicalTrials.gov under the company as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: HiberCell, Inc.; Biothera Pharmaceuticals
- Tags: ctgov-sponsor
- HQ: New York, NY
- Type: biotech
- Website: https://hibercell.com

## Sources

- Official website: https://hibercell.com
- ClinicalTrials.gov: trials led by HiberCell, Inc.: https://clinicaltrials.gov/search?lead=HiberCell%2C%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q138859693

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/hibercell.json